Want to see IN:ARVEE full AI Analyst Report?
ARVEE Stock Chart & Stats
₹242.32
-₹0.03(-0.02%)
At close: 4:00 PM EST
₹242.32
-₹0.03(-0.02%)
Day’s Range― - ―
52-Week Range₹129.11 - ₹290.78
Previous CloseN/A
Volume716.00
Average Volume (3M)1.40K
Market Cap
₹1.82B
Enterprise Value₹1.86B
Total Cash (Recent Filing)₹59.75M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)71.0
Beta1.28
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.24
Shares Outstanding11,020,000
10 Day Avg. Volume2,098
30 Day Avg. Volume1,398
Financial Highlights & Ratios
PEG Ratio3.35
Price to Book (P/B)4.37
Price to Sales (P/S)4.69
P/FCF Ratio-50.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and steadily growing equity provide durable financial flexibility. This lowers refinancing risk, supports counter-cyclical spending, and preserves capacity for capex or M&A when demand recovers, making the business more resilient over a multi-quarter horizon.
Historical Cash-generation Track RecordPrior multi-year positive operating and free cash flow indicate the company can generate cash in normal cycles. That historical capability suggests cash conversion dynamics and operational levers exist to restore cash flow when revenue stabilizes, reducing long-term liquidity risk.
Positive Profitability MarginsSustained gross margins and a positive net margin (~8%) show the core specialty-chemicals business retains pricing power or cost efficiency. Even with volatility, structural marginability supports future cash generation and reinvestment if top-line declines are addressed.
Bears Say
Negative Recent Cash FlowRecent negative operating and free cash flow indicate current earnings are not translating into liquidity, likely from working-capital swings or elevated spend. Prolonged cash absorption can force external financing or curtail investments, weakening durable financial flexibility.
Revenue VolatilitySharp cyclical swings in revenue reflect unstable demand or pricing in the specialty-chemicals market. Persistent top-line volatility undermines planning, compresses operating leverage, and raises the risk that temporary recovery measures may not sustain long-term growth.
Margin Pressure & Earnings QualityMargins have trended down from peak levels and earnings quality is weakened by falling sales. If contractions persist, the company may face structural margin erosion from fixed costs and reduced pricing power, impairing durable profitability and cash conversion.
Arvee Laboratories (India) Ltd. News
ARVEE FAQ
What was Arvee Laboratories (India) Ltd.’s price range in the past 12 months?
Arvee Laboratories (India) Ltd. lowest stock price was ₹129.11 and its highest was ₹290.78 in the past 12 months.
What is Arvee Laboratories (India) Ltd.’s market cap?
Arvee Laboratories (India) Ltd.’s market cap is ₹1.82B.
When is Arvee Laboratories (India) Ltd.’s upcoming earnings report date?
Arvee Laboratories (India) Ltd.’s upcoming earnings report date is Aug 18, 2026 which is in 44 days.
How were Arvee Laboratories (India) Ltd.’s earnings last quarter?
Arvee Laboratories (India) Ltd. released its earnings results on May 19, 2026. The company reported ₹0.47 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.47.
Is Arvee Laboratories (India) Ltd. overvalued?
According to Wall Street analysts Arvee Laboratories (India) Ltd.’s price is currently Overvalued.
Does Arvee Laboratories (India) Ltd. pay dividends?
Arvee Laboratories (India) Ltd. does not currently pay dividends.
What is Arvee Laboratories (India) Ltd.’s EPS estimate?
Arvee Laboratories (India) Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arvee Laboratories (India) Ltd. have?
Arvee Laboratories (India) Ltd. has 11,020,000 shares outstanding.
What happened to Arvee Laboratories (India) Ltd.’s price movement after its last earnings report?
Arvee Laboratories (India) Ltd. reported an EPS of ₹0.47 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5.463%.
Which hedge fund is a major shareholder of Arvee Laboratories (India) Ltd.?
Currently, no hedge funds are holding shares in IN:ARVEE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Arvee Laboratories (India) Ltd.
Arvee Laboratories (India) Ltd., established in 2012 and headquartered in Ahmedabad, India, specializes in the production and distribution of various specialized chemicals throughout the country. The company's product line includes a range of polymer modifiers, such as dimethyl 5-sodiosulfoisophthalate, 5-sulfoisophthalic acid mono sodium salt, 5-sulfoisophthalic acid mono lithium salt, and 5-sodiosulfo-bis-(ß-hydroxyethyl)-isophthalate. Additionally, Arvee Laboratories manufactures intermediates critical for contrast media, supplying compounds like 5-nitroisophthalic acid, dimethyl 5-nitroisophthalate, monomethyl 5-nitroisophthalate, 5-hydroxyisophthalic acid, 5-aminoisophthalic acid, dimethyl 5-aminoisophthalate, 3,5-dinitrobenzoic acid, and 3,5-diamino benzoic acid. The firm also provides drug intermediates, specifically 2-acetyl thiophene, thiophene-2-carboxaldehyde, 4-amino pyridine, and 2-chloro-5-nitrobenzoic acid. Beyond its domestic sales, Arvee Laboratories actively exports its chemical products.
Technical Analysis
Balaxi Pharmaceuticals Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
―
Lasa Supergenerics Ltd.
―
Vivimed Labs Limited
―